{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:59:09Z","timestamp":1791593949554,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR003096"],"award-info":[{"award-number":["UL1TR003096"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019192","name":"Center for Clinical and Translational Science, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020729","name":"Choquette Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20A0-KB"],"award-info":[{"award-number":["GUIMBE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK072482"],"award-info":[{"award-number":["DK072482"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jchromb.2022.123518","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T13:06:25Z","timestamp":1667480785000},"page":"123518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate"],"prefix":"10.1016","volume":"1213","author":[{"given":"Kevin J.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedria D.","family":"Reed-Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corenna D.","family":"Kerstner-Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2022.123518_b0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.clinbiochem.2012.05.034","article-title":"Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy","volume":"45","author":"Lubamba","year":"2012","journal-title":"Clin. Biochem"},{"key":"10.1016\/j.jchromb.2022.123518_b0010","doi-asserted-by":"crossref","unstructured":"B.W. Ramsey, J. Davies, N.G. McElvaney, E. Tullis, S.C. Bell, P. Drevinek, M. Griese, E.F. McKone, C.E. Wainwright, M.W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S.M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordonez, J.S. Elborn, V.X.S. Group, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365 (2011) 1663-1672.","DOI":"10.1056\/NEJMoa1105185"},{"key":"10.1016\/j.jchromb.2022.123518_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jchromb.2022.123518_b0020","unstructured":"H.G.M. Heijerman, E.F. McKone, D.G. Downey, E. Van Braeckel, S.M. Rowe, E. Tullis, M.A. Mall, J.J. Welter, B.W. Ramsey, C.M. McKee, G. Marigowda, S.M. Moskowitz, D. Waltz, P.R. Sosnay, C. Simard, N. Ahluwalia, F. Xuan, Y. Zhang, J.L. Taylor-Cousar, K.S. McCoy, V.X.T. Group, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial, Lancet, DOI https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8(2019)."},{"key":"10.1016\/j.jchromb.2022.123518_b0025","doi-asserted-by":"crossref","unstructured":"P.G. Middleton, M.A. Mall, P. Drevinek, L.C. Lands, E.F. McKone, D. Polineni, B.W. Ramsey, J.L. Taylor-Cousar, E. Tullis, F. Vermeulen, G. Marigowda, C.M. McKee, S.M. Moskowitz, N. Nair, J. Savage, C. Simard, S. Tian, D. Waltz, F. Xuan, S.M. Rowe, R. Jain, V.X.S. Group, Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, N Engl J Med, 381 (2019) 1809-1819.","DOI":"10.1056\/NEJMoa1908639"},{"key":"10.1016\/j.jchromb.2022.123518_b0030","unstructured":"Drug Approval Package: Trikafta, Food and Drug Administration, Food and Drug Administration."},{"key":"10.1016\/j.jchromb.2022.123518_b0035","unstructured":"Symdeko (tezacaftor\/ivacaftor) Oral Tablet, Food and Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000TOC.cfm."},{"key":"10.1016\/j.jchromb.2022.123518_b0040","unstructured":"Drug Approval Package: Kalydeco (ivacaftor), Food and Drug Administration, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188s000TOC.cfm."},{"key":"10.1016\/j.jchromb.2022.123518_b0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2013.08.008","article-title":"Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis","volume":"13","author":"Dalboge","year":"2014","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ppul.23638","article-title":"Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients","volume":"52","author":"Schultz","year":"2017","journal-title":"Pediatr. Pulmonol"},{"key":"10.1016\/j.jchromb.2022.123518_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jac\/1.suppl_3.59","article-title":"Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes","volume":"1","author":"Parsons","year":"1975","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.jchromb.2022.123518_b0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3476(05)80250-1","article-title":"Altered prednisolone pharmacokinetics in patients with cystic fibrosis","volume":"120","author":"Dove","year":"1992","journal-title":"J. Pediatr"},{"key":"10.1016\/j.jchromb.2022.123518_b0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","article-title":"Drug disposition in cystic fibrosis","volume":"35","author":"Rey","year":"1998","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.jchromb.2022.123518_b0070","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.jcf.2021.06.001","article-title":"Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?","volume":"20","author":"Jeyaratnam","year":"2021","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0075","unstructured":"R. Balijepally, D. Kwong, L. Zhu, J.V. Camacho, A. Liu, Elexacaftor\/tezacaftor\/ivacaftor outpatient desensitization, Ann Allergy Asthma Immunol, DOI https:\/\/doi.org\/10.1016\/j.anai.2021.08.010(2021)."},{"key":"10.1016\/j.jchromb.2022.123518_b0080","unstructured":"S. Lowry, P.J. Mogayzel, K. Oshima, W. Karnsakul, Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor, J Cyst Fibros, DOI https:\/\/doi.org\/10.1016\/j.jcf.2021.07.001(2021)."},{"key":"10.1016\/j.jchromb.2022.123518_b0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: When it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0090","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0095","unstructured":"M.K. Hu, G. Wood, O. Dempsey, 'Triple therapy' (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis, Postgrad Med J, DOI 10.1136\/postgradmedj-2020-139264(2020)."},{"key":"10.1016\/j.jchromb.2022.123518_b0100","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: Preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr. Pulmonol"},{"key":"10.1016\/j.jchromb.2022.123518_b0105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010023","article-title":"Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.jchromb.2022.123518_b0115","unstructured":"G.G. Spoletini, L.; Pollard, K.; Shaw, N.; Williams, E.; Etherington, C.; Clifton, I.J.; Peckham, D.G., Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis, Journal of Cystic Fibrosis, DOI https:\/\/doi.org\/10.1016\/j.jcf.2022.05.001(2022)."},{"key":"10.1016\/j.jchromb.2022.123518_b0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.01.011","article-title":"Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy","volume":"19","author":"Guimbellot","year":"2020","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0125","unstructured":"K. Habler, A.S. Kalla, M. Rychlik, M. Bruegel, D. Teupser, S. Nahrig, M. Vogeser, M. Paal, Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum, Clin Chem Lab Med, DOI https:\/\/doi.org\/10.1515\/cclm-2021-0724(2021)."},{"key":"10.1016\/j.jchromb.2022.123518_b0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jchromb.2022.123518_b0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jchromb.2013.11.054","article-title":"A sensitive HPLC-MS\/MS method for the determination of dolutegravir in human plasma","volume":"945\u2013946","author":"Bennetto-Hood","year":"2014","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jchromb.2022.123518_b0140","unstructured":"US Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry,in: US Department of Health and Human Services, https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf, 2018."},{"key":"10.1016\/j.jchromb.2022.123518_b0150","unstructured":"Code of Federal Regulations Code of Federal Regulations, https:\/\/www.ecfr.gov\/, United States of America, 2022."},{"key":"10.1016\/j.jchromb.2022.123518_b0155","unstructured":"Code of Federal Regulations Code of Federal Regulations https:\/\/www.ecfr.gov\/, United States of America, 2022."},{"key":"10.1016\/j.jchromb.2022.123518_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092706","article-title":"Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.jchromb.2022.123518_b0165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J. Cyst. Fibros"},{"key":"10.1016\/j.jchromb.2022.123518_b0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J. Cyst. Fibros"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222004238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222004238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:09:36Z","timestamp":1761606576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023222004238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"alternative-id":["S1570023222004238"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123518","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123518"}}